Most recently, Forster was the CEO of Solace Pharmaceuticals.
Before joining Solace Pharma, Forster was the head of EU Development and of Development Operations in the EU & Asia at Pfizer.
Creabilis chairman George Horner III said that they are delighted that Eliot has joined Creabilis. His proven drug development experience will be extremely valuable as we work to further advance of exciting pipeline of clinical drug candidates.
“Eliot’s appointment is another important step in Creabilis bringing highly innovative treatments for skin diseases to market,” Horner said.